Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
IONS
IONS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IONS News
UniQure's Gene Therapy Faces FDA Challenges
5d ago
CNBC
Biogen Unveils New Research Data on Spinal Muscular Atrophy
5d ago
Newsfilter
Ionis Pharmaceuticals Unveils New Data for DAWNZERA at AAAAI 2026
Feb 27 2026
Newsfilter
Ionis Pharmaceuticals Receives FDA Priority Review for Olezarsen
Feb 26 2026
Newsfilter
Ionis Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 25 2026
seekingalpha
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results
Feb 25 2026
Benzinga
Ionis Pharmaceuticals Q4 2023 Earnings Report Analysis
Feb 25 2026
seekingalpha
Ionis Pharmaceuticals to Announce Q4 Earnings on February 25
Feb 24 2026
seekingalpha
Ionis Pharmaceuticals to Participate in Multiple Investor Conferences
Feb 19 2026
Newsfilter
Ionis Pharmaceuticals Adjusts Webcast Time for Q4 2025 Results
Feb 17 2026
Newsfilter
Ionis Pharmaceuticals to Host Webcast on February 25 for Q4 and Full Year 2025 Results
Feb 11 2026
Newsfilter
Clinical Benefits of High-Dose Nusinersen Confirmed in DEVOTE Study
Feb 04 2026
Globenewswire
Clinical Findings on High-Dose Nusinersen Published
Feb 04 2026
Newsfilter
Ionis Pharmaceuticals Insider Sold Shares Worth $323,490, According to a Recent SEC Filing
Jan 23 2026
Yahoo Finance
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
Jan 21 2026
Benzinga
Ionis Pharmaceuticals and Otsuka Gain EU Approval for Dawnzera to Treat Hereditary Angioedema
Jan 21 2026
seekingalpha
Show More News
